SecBot SecBot
8-K ·Filed Jul 13, 2026

OCGN

Ocugen, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001104659-26-082897
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The binding term sheet provides a clear path to non-dilutive revenue and validates OCU400's commercial potential outside the US. Traders should watch for the definitive agreement within 90 days and the Phase 3 topline readout in Q1 2027 as the next major catalysts. The 22% royalty rate is high and suggests strong partner commitment.

DirectionBullish
Confidencemedium
Horizonmonths

OCU400

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
Potential FDA approval in 2027-2028 if Phase 3 succeeds and BLA submission (targeted Q3 2026 rolling) is accepted.
Next catalyst
None dated

What to watchWatch for the rolling BLA submission in Q3 2026 as a validation event and the Phase 3 topline readout in Q1 2027 as the primary binary catalyst. The stock has strong institutional accumulation and analyst support (9 Buy, mean PT ~$11.43 vs ~$1.43), but remains pre-revenue with high dilution risk from $130M convertible notes. The Phase 1/2 data was encouraging, durability and a gene-agnostic approach differentiate OCU400 from the only approved therapy, Luxturna.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.41
T+0 close · Jul 13, 2026 · via day close
Latest settled
−26.24%
T+60 · $1.04
Vs SPY
−30.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $1.41entry
  2. T+1 · 4mo ago +1.42%α +1.06% · $1.43
  3. T+5 · 4mo ago −3.55%α −2.76% · $1.36
  4. T+20 · 3mo ago −7.09%α −10.28% · $1.31
  5. T+60 · 6w ago −26.24%α −30.23% · $1.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy for retinitis pigmentosa in the MENA region. The deal includes upfront/near-term milestones up to $4 million, cumulative sales milestones up to $255 million, and a 22% royalty on net sales, with Ocugen manufacturing commercial supply. A definitive agreement is expected within 90 days, and the Phase 3 liMeliGhT trial topline readout is expected in Q1 2027.

Key Facts

  • Binding term sheet signed with Roots Pharmaceutical for OCU400 license in MENA region
  • Upfront and near-term development milestones up to $4 million
  • Cumulative sales milestones up to $255 million
  • 22% royalty on net sales
  • Ocugen to manufacture and supply OCU400
  • Definitive agreement expected within 90 days
  • Phase 3 liMeliGhT topline readout expected in Q1 2027

Financial Impact

Upfront/near-term milestones up to $4M, cumulative sales milestones up to $255M, plus 22% royalty on net sales

revenuedilution

Risk Factors

  • Definitive agreement not yet executed, term sheet is binding but final terms may differ
  • OCU400 still in Phase 3 trials with topline readout not expected until Q1 2027
  • No revenue from this deal until regulatory approval and commercialization, which is years away

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-082897
Document: tm2620295d1_ex99-1.htm0001104659-26-082897
Document: 0001104659-26-082897-index-headers.html0001104659-26-082897
Document: 0001104659-26-082897-index.html0001104659-26-082897
Document: 0001104659-26-082897.txt0001104659-26-082897

Track record

23 reports on OCGN

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026